A comparative study on nonviral genetic modifications in cord blood and bone marrow mesenchymal stem cells

Abstract

The focus of both clinical and basic studies on stem cells is increasing due to their potentials in regenerative medicine and cell-based therapies. Recently stem cells have been genetically modified to enhance an existing character in or to bring a new property to them. However, accomplishment of declared goals requires detailed knowledge about their molecular characteristics which could be achieved by genetic modifications mostly through nonviral transfection strategies. Capable of differentiating into multiple cells, human unrestricted somatic stem cells (hUSSCs) and human mesenchymal stem cells (hMSCs) seem to be suitable candidates for transfection approaches. Involvement of microRNAs (miRNAs) in many biological processes makes their transfection evaluation valuable. Herein we investigated the efficacy and toxicity of four typically used transfection reagents (Arrest-In, Lipofectamine 2000, Oligofectamine and HiPerfect) systematically to deliver fluorescent labeled-miRNA and Green Fluorescent Protein (GFP) expressing plasmid into hUSSCs and hMSCs. The authenticity of stem cells was verified by differentiation experiments along with flow cytometry of surface markers. Our study revealed that stemness properties of these stem cells were not affected by transient transfection. Moreover the ratios of cell viability and transfection efficiency in both analyzed stem cells were reversed. Considering cell viability, the highest fraction of GFP-expressing cells was obtained using Oligofectamine (*50%) while the highest transfection rate of miRNA was achieved by Lipofectamine 2000 (*90%). Moreover dependency of hMSCs to size of transfected nucleic acid and timedependency of Oligofectamine and their affection on the yield of transfection were observed. Cytotoxicity assessments also showed that hUSSCs are sensitive to HiPerFect. In addition cells treated by Lipofectamine showed morphological changes. Representing the efficient nucleic acid transfection, our research facilitates comprehensive genetic modification of stem cells and demonstrates powerful approaches to understand stem cell molecular regulation mechanisms, Electronic supplementary material The online version of this article

Liposomes as carriers: not as innocent as one would like

“…That this view may be a little bit too simple has been brought to our attention by a thorough comparative study of the influence of three lipid-based transfection agents on hepatocytes focusing on various side effects on cellular metabolism presented in this issue of Archives of Toxicology (Böttger et al 2015). While this study confirmed the high efficiency of the tested transfection agents in silencing transcription of target genes by respective siRNAs together with a low cytotoxicity for the hepatocytes (Bakhshandeh et al 2012;Gao et al 2012), it demonstrated considerable effects on different aspects of lipid and amino acid metabolism of these cells (Böttger et al 2015). Using highly sophisticated shotgun lipidomics analysis, Böttger et al (2015) showed that all tested transfection agents altered the hepatocellular accumulation of triglycerides (two up and one down).…”

Engraftment of autologous bone marrow cells into the injured cranial cruciate ligament in dogs

“…However, use of GFP requires a gene transfer agent, such as a virus that is non-integrating or, preferably from a biosafety point of view, a non-viral vector. These, however, are limited by the requirement of large cell numbers, high levels of cell death and low transfection efficiency (Bakhshandeh et al, 2012).…”

MicroRNA replacement therapy in cancer

“…Therefore, lack of an effective delivery system of miRNAs still remains a major problem. Viral and nonviral vectors have been developed as two common types of vectors for delivery of miRNAs to solve the mentioned problems (Bakhshandeh, Soleimani, Hafizi, & Ghaemi, 2012). Moreover, a recent study conducted by Tavanafar et al (2017) indicated that restoration of miR-143 expression by plasmid vector (pCMV-MIR-143) in breast adenocarcinoma cells reduced KRAS, Vimentin, CXCR4, and MMP9 and increased E-Cadherin expression.…”